
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is supported by a broad, diversified portfolio of prescription drugs and vaccines that generated roughly $60 billion in annual sales, with international markets contributing 40% of revenue and emerging markets adding another growth lever. Its 3Q 2026 results were strong enough to lift FY 2026 revenue guidance to $62.0-64.0 billion and EPS guidance to $2.95-3.05, reflecting resilient demand for key products such as Vyndamax, Eliquis, and Nurtec, even as some COVID and Prevnar pressure persists. Beyond the core franchise, the outlook is strengthened by a maturing pipeline and multiple catalysts, including MEVPRO-1 data around February 2027 and obesity updates by the end of 2026, while international Vyndamax appears more durable through 2029 under EU orphan exclusivity.
Bears say
Pfizer is viewed negatively because its core business faces multiple pressure points, including disappointing execution on key products such as Padcev, Comirnaty, and Paxlovid, alongside the risk of clinical or regulatory setbacks in pipeline assets like berobenatide, PF'3945, PF'4404, and mevrometostat. Its 2026 guidance already reflects about $1.1 billion of negative year-over-year revenue impact from loss of exclusivity, while operating margins could be squeezed if the base business deteriorates faster than expected and EPS growth slows. Additional concern comes from expected weakness in Prevnar sales in 3Q26, with headwinds from declining vaccination rates, lower birth rates, and U.S. government vaccine policy, alongside macro risks from drug pricing reform and tariff changes that may compress investor sentiment.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pfizer (PFE) Forecast
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares